Immune Cell Therapy (ICT)

HQ Location

4737 South Kimbark Avenue
Chicago, IL 60615

Company Description

ICT has developed a unique and highly promising strategy for preparing vaccines for cancer therapy that have special advantages other types of cancer vaccines. The treatment consists of immunization with a vaccine that is designed to induce a powerful immune response against microscopic nests cancer cells remaining in patients who have completed conventional treatment (usually surgery, chemo/hormonal therapy and X-ray). Microscopic nests of residual cancer cells are the most common source of recurrence of the disease. The Company's initial focus is for patients with lung or breast cancer.

Recent News Headlines

(Boston Globe/Associated Press) Nov 3, 2016 - Doctors have found a disturbing downside to some powerful new drugs that harness the immune system to fight cancer: In rare cases, they may cause potentially fatal heart damage, especially when used together.

(Reuters Health) Oct 21, 2016 - People with type 1 diabetes often develop other autoimmune disorders, such as thyroid and gastrointestinal diseases, and a recent study yields new information about this link.

(The Wistar Institute) Oct 14, 2016 - While the role of estrogen signaling in tumor development is well understood in breast and ovarian cancer, its role in anti-tumor immunity has not been extensively studied. However, new research from The Wistar Institute showed that estrogen signaling was responsible for immunosuppressive effects in the tumor microenvironment across cancer types.

(Yahoo! Finance) Oct 11, 2016 - CA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration.

(Boehringer Ingelheim) Sept 29, 2016 - Boehringer Ingelheim and Sarah Cannon Research Institute, the research arm of Sarah Cannon, the global cancer institute of HCA, announced today a new strategic collaboration. This partnership brings together Boehringer Ingelheim's extensive experience in cancer drug development and Sarah Cannon's expertise and leadership in designing and optimizing clinical trials. The partnership will help bring innovative cancer treatments to patients with unmet medical needs.

(NASDAQ) Sept 26, 2016 - Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, and The University of Texas MD Anderson Cancer Center announced today that they have entered into a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer.

(Reuters) Sept 26, 2016 - Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease.

(AACR) Sept 26, 2016 - Among patients with stage IV melanoma who were being treated with the immunotherapeutic pembrolizumab (Keytruda), the ratio of a particular subset of immune cells in the blood to tumor burden correlated with clinical response, according to data presented at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 25–28.